CCM
VIVO

Catawba Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Catawba Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,265
Closed -$161K – 227
2017
Q3 		$161K Sell
11,265
-2,100
-16% -$30K 0.04% 219
2017
Q2 		$210K Sell
13,365
-1,700
-11% -$24.5K 0.05% 221
2017
Q1 		$208K Hold
15,065
– – 0.05% 243
2016
Q4 		$267K Hold
15,065
– – 0.06% 207
2016
Q3 		$291K Buy
+15,065
New +$295K 0.07% 194

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Catawba Capital Management's VIVO Position: Q4 2017 in Review

Catawba Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2017, closing a stake of 11,265 shares — an estimated $161K sold.

Catawba Capital Management first reported a position in VIVO in Q3 2016 and held it in 5 quarters. The position peaked at $291K in Q3 2016. 178 funds tracked by Wall St. Rank hold VIVO as of Q4 2017.

  • Catawba Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2017 after selling out during the quarter.
  • Catawba Capital Management sold 11,265 Meridian Bioscience Inc shares in Q4 2017, an estimated $161K.
  • Catawba Capital Management first reported a position in Meridian Bioscience Inc in Q3 2016 and held it in 5 quarters.
  • Catawba Capital Management's Meridian Bioscience Inc position peaked at $291K in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2017.

Based on Catawba Capital Management's 13F filing for Q4 2017, filed 19 Jan 2018.